ZeroHarm Sciences has raised ₹65 crore ($7.15 million) in a Series A funding round, with ₹40 crore coming from Kotak Alternate Asset Managers Limited through its Kotak Life Sciences Fund I, and ₹25 crore invested by Alkemi Growth Capital.
The company said the capital will be used to strengthen brand presence across India, expand into international markets including the US, UK, and the Middle East, and scale up its research and manufacturing operations.
Launched in 2020 by Sachin Darbarwar and Shweta Darbarwar, ZeroHarm Sciences works on advanced nutraceutical formulations that use nanotechnology to help the body absorb plant-based nutrients more efficiently, enabling effective results with smaller quantities.
Based in Hyderabad, the company integrates Ayurvedic principles with modern science to offer preventive wellness solutions. It manages its supply chain end to end, sourcing medicinal plants through a network of more than 10,000 farmers across the Northeast and Himalayan regions.
ZeroHarm’s portfolio includes over 60 products spanning diabetes care, heart health, joint support, immunity, gut health, women’s wellness, oncology support, and performance nutrition. Its products are sold through its own website, major e-commerce platforms, and quick commerce channels, and the brand has served over 3 lakh customers to date.
